On July 27, 2022 EVERSANA reported at 7th Annual CAR-TCR Summit (Press release, EVERSANA, JUL 27, 2022, View Source [SID1234617003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the industry focuses more on specialty therapies, it is imperative that manufacturers move to a patient-centered care model that delivers value enabled by innovative technologies and measured by actionable data.

As the only go-to complete commercialization expert in the industry, EVERSANATM brings together strategy, patient recruitment for clinical trials, HCPs and patient engagement across the patient journey, and warehousing and logistics to support complex transportation needs.

Join EVERSANA’s Brian Urban, Senior Implementation Director and Seth Gordon, General Manager, EVERSANA INTOUCH Engage during their September 21st plenary presentation, "Incorporating Patient Insights & Engagement for Clinical & Commercial Success," at 8:40 am EST.

To schedule a meeting with our cell and gene therapy experts at the CAR-TCR Summit, click here.

On July 27, 2022 EVERSANA reported to be a Summit Partner at this year’s DTx East Summit taking place September 27-29 in Boston (Press release, EVERSANA, JUL 27, 2022, View Source [SID1234617002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Join EVERSANA and other leaders in the industry as we advance the conversation on:

Commercializing digital therapeutics by navigating the local regulatory pathways to approval
Advancing the adoption of companion apps
Securing broad payer coverage and reimbursement for digital therapies
The DTx summits are the premier event series for senior executives from DTx companies, and pharma, investors, HCPs, payers and more. DTx East 2021 is the ninth summit in the DTx series. The industry leaders and most exciting newcomers will be in attendance across an in-person and online event.

On July 27, 2022 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") reported the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA) (Press release, Dr Reddy’s, JUL 27, 2022, View Source [SID1234617001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.

Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Velcade is a trademark of Takeda Pharmaceuticals U.S.A., Inc.

*IQVIA Retail and Non-Retail MAT May 2022

RDY-0722-430

On July 27, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2022 (Press release, Delcath Systems, JUL 27, 2022, View Source [SID1234617000]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. (PRNewsfoto/Delcath Systems, Inc.)

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

On July 27, 2022 Corcept Therapeutics Incorporated (NASDAQ: CORT) reported it will report second quarter financial results and provide a corporate update on August 3, 2022 (Press release, Corcept Therapeutics, JUL 27, 2022, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announce-second-quarter-financial-results-5 [SID1234616999]). The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clicking here.

A replay of the call will be available on the Investors / Events tab of www.corcept.com.